Yahoo
NasdaqCM - Delayed Quote USD

Liminatus Pharma, Inc. (LIMN)

5.16 -0.47 (-8.35%)
At close: August 21 at 4:00:00 PM EDT
5.18 +0.03 (+0.58%)
Pre-Market: 9:09:24 AM EDT
Chart Range Bar
Loading chart for LIMN
  • Previous Close 5.63
  • Open 5.53
  • Bid 1.32 x 500
  • Ask 0.11 x 2900
  • Day's Range 5.15 - 5.88
  • 52 Week Range 4.75 - 180.00
  • Volume 116,539
  • Avg. Volume 706,551
  • Market Cap (intraday) 6.931M
  • Beta (5Y Monthly) 0.74
  • PE Ratio (TTM) --
  • EPS (TTM) -24.00
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.

liminatuspharma.com

1

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 8/21/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

LIMN
83.08%
S&P 500 (^GSPC)
12.11%

1-Year Return

LIMN
96.29%
S&P 500 (^GSPC)
20.47%

3-Year Return

LIMN
98.87%
S&P 500 (^GSPC)
74.43%

5-Year Return

LIMN
98.87%
S&P 500 (^GSPC)
72.78%

Statistics

View More

Valuation Measures

Annual
As of 8/21/2026
  • Market Cap

    6.92M

  • Enterprise Value

    5.34M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    23.01

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -95.65%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -12.52M

  • Diluted EPS (ttm)

    -24.00

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.02M

  • Total Debt/Equity (mrq)

    479.85%

  • Levered Free Cash Flow (ttm)

    -10.01M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

5.16 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: